Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 5:17 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1417–1440 of 3,863 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: SC Clear all
Completed Phase 1Phase 2 Interventional Results available

Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System

NCT00520130
View directory record Official record
Conditions
Myelodysplastic Syndrome, Hodgkin's Lymphoma, Non-Hodgkin's Disease, Acute Leukemia, Multiple Myeloma
Interventions
Rituximab, Cyclosporine, Allogenic stem cell transplant (ASCT), Conditioning Chemotherapy, TMS, FLAG, EPOCH-F, Alemtuzumab
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 74 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Nov 2, 2026, 5:17 PM EST
Active, not recruiting Phase 2Phase 3 Interventional

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

NCT05531565
View directory record Official record
Conditions
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
Interventions
Litifilimab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
62
States / cities
Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 2, 2026, 5:17 PM EST
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)

NCT05277571
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
UCB1381, Placebo
Biological · Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 65 Years
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
16
States / cities
Beverly Hills, California • Glendale, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Nov 2, 2026, 5:17 PM EST
Completed Phase 3 Interventional Results available

A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine

NCT03559257
View directory record Official record
Conditions
Migraine
Interventions
Galcanezumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
18
States / cities
Phoenix, Arizona • San Diego, California • Ocoee, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Nov 2, 2026, 5:17 PM EST
Completed Phase 3 Interventional

A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis

NCT00081471
View directory record Official record
Conditions
Anemia
Interventions
darbepoetin alfa, methoxy polyethylene glycol-epoetin beta [Mircera]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
22
States / cities
Los Angeles, California • Mather, California • Stanford, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Nov 2, 2026, 5:17 PM EST
Recruiting Phase 3 Interventional

Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy

NCT06745908
View directory record Official record
Conditions
NSCLC Stage IV
Interventions
N-803, Tislelizumab, Docetaxel, Prior failed checkpoint inhibitor
Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
32
States / cities
Hot Springs, Arkansas • Springdale, Arkansas • El Segundo, California + 26 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 2, 2026, 5:17 PM EST
Terminated Phase 3 Interventional Results available

Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019

NCT01797965
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
Interventions
BIIB019 (Daclizumab)
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
1,501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
39
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2019 · Synced Nov 2, 2026, 5:17 PM EST
Completed Phase 2 Interventional Results available

A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Participants With Atopic Dermatitis (AD)

NCT03921411
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Nemolizumab
Biological
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
10
States / cities
Fountain Valley, California • Fremont, California • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2023 · Synced Nov 2, 2026, 5:17 PM EST
Completed Phase 4 Interventional Results available

Risedronate and Parathyroid Hormone to Reverse Osteoporosis Caused by Chronic Steroid Use

NCT00221299
View directory record Official record
Conditions
Osteoporosis
Interventions
Risedronate, Parathyroid Hormone
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2015 · Synced Nov 2, 2026, 5:17 PM EST
Completed Phase 2 Interventional

A Study Evaluating the Safety and Clinical Activity of HCV-796 in Treatment-Naive and Non-Responder Subjects

NCT00367887
View directory record Official record
Conditions
Hepatitis C
Interventions
Peg-Intron, REBETOL, HCV 796
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
34
States / cities
Anaheim, California • La Jolla, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Nov 2, 2026, 5:17 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety and Tolerability of Single Doses of REGN1500

NCT01749878
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
REGN1500, placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Nov 2, 2026, 5:17 PM EST
Completed Phase 1 Interventional Results available

Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

NCT03388632
View directory record Official record
Conditions
Metastatic Solid Tumors, Treatment-Refractory Cancers
Interventions
rhIL-15, Ipilimumab, Nivolumab, Tumor biopsies, EKG, ECHO, CT Scan
Drug · Procedure · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Nov 2, 2026, 5:17 PM EST
Completed Phase 1 Interventional

A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants

NCT05445232
View directory record Official record
Conditions
Obesity
Interventions
LY3437943, Midazolam, Warfarin, Caffeine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Nov 2, 2026, 5:17 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioequivalence Study of Subcutaneous (SC) Lebrikizumab Administered by Needle and Syringe or by Prefilled Syringe With Needle Safety Device (PFS-NSD)

NCT02486809
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Lebrikizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
4
States / cities
Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Nov 2, 2026, 5:17 PM EST
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Safety and Immunogenicity Trial in Adults 65 Years of Age or Over to Prevent Influenza

NCT00706732
View directory record Official record
Conditions
Influenza
Interventions
AVX502, Placebo
Biological
Lead sponsor
AlphaVax, Inc.
Industry
Eligibility
65 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2012 · Synced Nov 2, 2026, 5:17 PM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)

NCT03893448
View directory record Official record
Conditions
Pneumococcal Infections, Pneumococcal Vaccines
Interventions
V114, Prevnar 13™, RotaTeq™, Pentacel™, RECOMBIVAX HB™, VAQTA™, MMR II™, VARIVAX™, HIBERIX™
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
42 Days to 90 Days
Enrollment
1,720 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
66
States / cities
Birmingham, Alabama • Dothan, Alabama • Opp, Alabama + 58 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2023 · Synced Nov 2, 2026, 5:17 PM EST
Suspended Phase 2 Interventional

Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Active, Stable, Moderate to Severe Rheumatoid Arthritis

NCT00777816
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
XOMA 052, Placebo
Drug
Lead sponsor
XOMA (US) LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
2
States / cities
Clearwater, Florida • Middleburg Heights, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 29, 2015 · Synced Nov 2, 2026, 5:17 PM EST
Active, not recruiting Phase 2 Interventional

Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita

NCT01659606
View directory record Official record
Conditions
Dyskeratosis Congenita, Hoyeraal Hreidarsson Syndrome, Revesz Syndrome, Aplastic Anemia
Interventions
alemtuzumab, Fludarabine, Cyclosporins, Mycophenolate mofetil, Tacrolimus
Biological · Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
30 Days to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2034
U.S. locations
11
States / cities
Chicago, Illinois • Boston, Massachusetts • Kansas City, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Nov 2, 2026, 5:17 PM EST
Withdrawn Phase 2 Interventional

A Clinical Trial to Evaluate the Efficacy of Abatacept in Moderate to Severe Alopecia Areata

NCT01917058
View directory record Official record
Conditions
Alopecia Areata
Interventions
Abatacept, placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Nov 2, 2026, 5:17 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic, Safety/Tolerability Study of a Single SC Dose of PB1023 Injection in Subjects With Normal and Impaired Renal Function

NCT01478399
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
PB1023 Injection
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Saint Paul, Minnesota • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 15, 2013 · Synced Nov 2, 2026, 5:17 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Safety, Tolerability, PK and PD of AZD2373 in Healthy Male Participants of Sub-Saharan West African Ancestry

NCT05351047
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AZD2373 subcutaneous injection, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 7, 2023 · Synced Nov 2, 2026, 5:17 PM EST
Completed Phase 3 Interventional Results available

Usability Study of the Commercial Auto-injector Device and the New Auto-injector Device (SYDNEY) in Patients With High or Very High CV Risk With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy

NCT03415178
View directory record Official record
Conditions
Hypercholesterolaemia
Interventions
Alirocumab SAR236553, Current auto-injector device (AI), New auto-injector device (SYDNEY), Atorvastatin, Rosuvastatin
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
13
States / cities
Los Angeles, California • Jacksonville, Florida • Ponte Vedra, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Nov 2, 2026, 5:17 PM EST
Active, not recruiting Phase 1 Interventional

Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma

NCT02337985
View directory record Official record
Conditions
AIDS-Related Burkitt Lymphoma, AIDS-Related Diffuse Large B-cell Lymphoma, AIDS-Related Plasmablastic Lymphoma, AIDS-Related Primary Effusion Lymphoma, HIV Infection, AIDS Related Non-Hodgkin Lymphoma
Interventions
Prednisone, Rituximab, Etoposide, Doxorubicin Hydrochloride, Vincristine Sulfate, Cyclophosphamide, Filgrastim, Lentivirus Vector rHIV7-shI-TAR-CCR5RZ-transduced Hematopoietic Stem/Progenitor Cells
Drug · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Nov 2, 2026, 5:17 PM EST
Completed Phase 3 Interventional

A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.

NCT00744926
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
placebo, taspoglutide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 80 Years
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
10
States / cities
Phoenix, Arizona • Los Angeles, California • Santa Ana, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2016 · Synced Nov 2, 2026, 5:17 PM EST